Company intelligence / Profile preview

鼎新基因

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

鼎新基因 is developing a proprietary gene therapy platform using both AAV viral vectors and non-virus-based delivery systems. The company is currently in the pre-clinical stage with a focus on precision solutions for eye, ear, and heart conditions. No clinical results have been published yet.

Therapeutic areas: OphthalmologyCardiovascularOther
Modalities: Gene therapyViral vector (AAV)Non-viral vector
Industry: Biotech

Beyond the preview

Go deeper on 鼎新基因.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 鼎新基因.

Explore the full profile